Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) has earned an average rating of “Buy” from the ten research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $37.00.
A number of research firms have recently weighed in on RHHBY. ValuEngine cut Roche Holdings AG Basel from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. UBS Group raised Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a report on Friday, July 26th. Finally, Zacks Investment Research raised Roche Holdings AG Basel from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a report on Tuesday, July 9th.
Shares of RHHBY traded up $0.02 during mid-day trading on Wednesday, reaching $37.02. 1,484,398 shares of the company’s stock traded hands, compared to its average volume of 1,256,308. The business’s 50-day moving average price is $35.90 and its 200-day moving average price is $34.40. The stock has a market capitalization of $251.34 billion, a P/E ratio of 15.96, a price-to-earnings-growth ratio of 2.30 and a beta of 0.49. Roche Holdings AG Basel has a 12 month low of $28.77 and a 12 month high of $37.18.
Several hedge funds and other institutional investors have recently bought and sold shares of RHHBY. Colony Group LLC acquired a new position in shares of Roche Holdings AG Basel during the second quarter valued at approximately $6,887,000. Schafer Cullen Capital Management Inc grew its position in Roche Holdings AG Basel by 10.9% in the second quarter. Schafer Cullen Capital Management Inc now owns 1,953,425 shares of the company’s stock worth $65,127,000 after buying an additional 192,360 shares during the last quarter. Douglass Winthrop Advisors LLC grew its position in Roche Holdings AG Basel by 19.8% in the third quarter. Douglass Winthrop Advisors LLC now owns 764,226 shares of the company’s stock worth $27,856,000 after buying an additional 126,248 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in Roche Holdings AG Basel by 1.7% in the second quarter. Parametric Portfolio Associates LLC now owns 5,499,135 shares of the company’s stock worth $193,020,000 after buying an additional 91,821 shares during the last quarter. Finally, Meritage Portfolio Management grew its position in Roche Holdings AG Basel by 382.1% in the third quarter. Meritage Portfolio Management now owns 90,048 shares of the company’s stock worth $3,282,000 after buying an additional 71,370 shares during the last quarter. Institutional investors and hedge funds own 0.32% of the company’s stock.
About Roche Holdings AG Basel
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Read More: Capital Gains Distribution
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.